New York, Feb 24, 2026, 08:49 EST — Premarket
- BillionToOne shares slid about 16% in the previous session, closing at $72.10.
- The diagnostics maker is due to report fourth-quarter and full-year results on March 4.
- Investors are watching for signs demand is holding up as the company scales prenatal and oncology testing.
BillionToOne, Inc shares fell 15.7% in the previous session, ending at $72.10 after a sharp late-day slide that left the newly listed diagnostics firm among the day’s bigger decliners.
The drop matters now because BillionToOne is still early in its life as a public company, and the next clear checkpoint is close. Its fourth-quarter and full-year report is set for March 4, when investors will get a fuller look at volumes, pricing and costs. (BioSpace)
BillionToOne has not posted a new press release since Feb. 17, when it said it would report results on March 4. That left traders leaning on positioning and broader risk appetite to explain Monday’s move. (Billiontoone)
The Menlo Park, California-based company sells molecular diagnostics in prenatal screening and oncology, using its technology to measure tiny fragments of DNA. Its test menus put it in crowded lanes that include prenatal screening rivals and liquid-biopsy specialists. (Reuters)
U.S. stocks were lower on Monday, but BillionToOne’s drop was far steeper than the major indexes’ declines. In that tape, smaller healthcare names that had held up earlier in the year drew profit-taking. (Yahoo Finance)
With results a little more than a week away, investors are likely to focus on test volumes and mix, along with how quickly the company can expand in oncology without giving up margin. Reimbursement trends will be in the frame, too, because coverage decisions can move diagnostics revenue quickly.
The company in January laid out its 2026 outlook, including revenue guidance of $415 million to $430 million and an expectation of positive GAAP operating income for the year. That set a bar, and Monday’s selloff suggests some investors are reassessing how much of that is already priced in. (Billiontoone)
Competition is another pressure point. Prenatal screening is a tough market with well-funded incumbents, and liquid biopsy has turned into a land grab, with payers and health systems pushing hard on evidence and cost.
But the next read is not a rumor mill item. It is the March 4 report and conference call, when management will have to put numbers behind growth claims, and explain any stumbles in demand, pricing or execution.
